JP2018505893A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505893A5
JP2018505893A5 JP2017541808A JP2017541808A JP2018505893A5 JP 2018505893 A5 JP2018505893 A5 JP 2018505893A5 JP 2017541808 A JP2017541808 A JP 2017541808A JP 2017541808 A JP2017541808 A JP 2017541808A JP 2018505893 A5 JP2018505893 A5 JP 2018505893A5
Authority
JP
Japan
Prior art keywords
domain
human igg
glycosylated
variant human
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541808A
Other languages
English (en)
Japanese (ja)
Other versions
JP6724023B2 (ja
JP2018505893A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/017100 external-priority patent/WO2016130516A1/en
Publication of JP2018505893A publication Critical patent/JP2018505893A/ja
Publication of JP2018505893A5 publication Critical patent/JP2018505893A5/ja
Priority to JP2020108886A priority Critical patent/JP6926285B2/ja
Application granted granted Critical
Publication of JP6724023B2 publication Critical patent/JP6724023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541808A 2015-02-09 2016-02-09 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド Active JP6724023B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020108886A JP6926285B2 (ja) 2015-02-09 2020-06-24 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113717P 2015-02-09 2015-02-09
US62/113,717 2015-02-09
PCT/US2016/017100 WO2016130516A1 (en) 2015-02-09 2016-02-09 Engineered immunoglobulin fc polypeptides displaying improved complement activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020108886A Division JP6926285B2 (ja) 2015-02-09 2020-06-24 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド

Publications (3)

Publication Number Publication Date
JP2018505893A JP2018505893A (ja) 2018-03-01
JP2018505893A5 true JP2018505893A5 (enExample) 2018-12-27
JP6724023B2 JP6724023B2 (ja) 2020-07-15

Family

ID=55442874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017541808A Active JP6724023B2 (ja) 2015-02-09 2016-02-09 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
JP2020108886A Active JP6926285B2 (ja) 2015-02-09 2020-06-24 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020108886A Active JP6926285B2 (ja) 2015-02-09 2020-06-24 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド

Country Status (6)

Country Link
US (2) US10457737B2 (enExample)
EP (1) EP3256490A1 (enExample)
JP (2) JP6724023B2 (enExample)
AU (1) AU2016219511B2 (enExample)
CA (1) CA2976236A1 (enExample)
WO (1) WO2016130516A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN110461868A (zh) * 2016-11-01 2019-11-15 根马布私人有限公司 多肽变体及其用途
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
WO2020045545A1 (ja) * 2018-08-29 2020-03-05 中外製薬株式会社 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
CN115768880A (zh) * 2020-05-06 2023-03-07 亘喜生物科技（上海）有限公司 用于t细胞工程化的组合物和方法
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
MX2023006899A (es) * 2020-12-10 2023-09-04 Invenra Inc Mutaciones ortogonales para heterodimerización.
US20240425612A1 (en) * 2021-10-18 2024-12-26 Korea University Research And Business Foundation Fc variants having improved ph-dependent fcrn binding capacity and fcriiia binding selectivity
EP4430179A1 (en) * 2021-11-11 2024-09-18 The Macfarlane Burnet Institute for Medical Research and Public Health Limited Antiviral agent comprising a cellular entry receptor and fc region component
CN119421902A (zh) * 2021-11-11 2025-02-11 麦克法兰布奈特医疗研究与公共健康研究所有限公司 包括在位置429处具有突变的fc区组分的免疫治疗蛋白
WO2024229535A1 (en) * 2023-05-10 2024-11-14 Macfarlane Burnet Institute For Medical Research And Public Health Limited Immunotherapeutic proteins
AU2024269873A1 (en) * 2023-05-10 2025-11-27 Macfarlane Burnet Institute For Medical Research And Public Health Limited Immunotherapeutic proteins

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3826364A (en) 1972-05-22 1974-07-30 Univ Leland Stanford Junior Particle sorting method and apparatus
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4284412A (en) 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4498766A (en) 1982-03-25 1985-02-12 Becton, Dickinson And Company Light beam focal spot elongation in flow cytometry devices
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4661913A (en) 1984-09-11 1987-04-28 Becton, Dickinson And Company Apparatus and method for the detection and classification of articles using flow cytometry techniques
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4767206A (en) 1984-12-24 1988-08-30 Flow Cytometry Standards Corporation Calibration method for flow cytometry using fluorescent microbeads and synthesis thereof
US4774189A (en) 1984-12-24 1988-09-27 Flow Cytometry Standards Corp. Fluorescent calibration microbeads simulating stained cells
US4857451A (en) 1984-12-24 1989-08-15 Flow Cytometry Standards Corporation Method of compensating and calibrating a flow cytometer, and microbead standards kit therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4989977A (en) 1985-07-29 1991-02-05 Becton, Dickinson And Company Flow cytometry apparatus with improved light beam adjustment
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4714682A (en) 1985-12-11 1987-12-22 Flow Cytometry Standards Corporation Fluorescent calibration microbeads simulating stained cells
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
US4988618A (en) 1987-11-16 1991-01-29 Gene-Trak Systems Magnetic separation device and methods for use in heterogeneous assays
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5858652A (en) 1988-08-30 1999-01-12 Abbott Laboratories Detection and amplification of target nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US6018031A (en) 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
US5578464A (en) 1989-10-31 1996-11-26 Schering Corporation E. coli secretory strains
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5160974A (en) 1990-06-25 1992-11-03 Flow Science, Inc. Closed sample cell for use in flow cytometry
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5478722A (en) 1991-02-17 1995-12-26 The Curators Of The University Of Missouri Preserved cell preparations for flow cytometry and immunology
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5994514A (en) 1991-08-14 1999-11-30 Genentech, Inc. Immunoglobulin variants
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5846709A (en) 1993-06-15 1998-12-08 Imclone Systems Incorporated Chemical process for amplifying and detecting nucleic acid sequences
FR2708288B1 (fr) 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
AU707391B2 (en) 1994-05-28 1999-07-08 Tepnel Medical Limited Producing copies of nucleic acids
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
JP3102800B2 (ja) 1994-08-19 2000-10-23 パーキン−エルマー コーポレイション 増幅及び連結反応の共役法
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5567326A (en) 1994-09-19 1996-10-22 Promega Corporation Multisample magnetic separation device
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5935825A (en) 1994-11-18 1999-08-10 Shimadzu Corporation Process and reagent for amplifying nucleic acid sequences
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US5916779A (en) 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
FR2739629B1 (fr) 1995-10-06 1997-12-26 Systems Bio Ind Utilisation d'un systeme de secretion sec-dependant pour secreter des proteines normalement secretees par un systeme de secretion sec-independant, bacteries les contenant et leur utilisation
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5939291A (en) 1996-06-14 1999-08-17 Sarnoff Corporation Microfluidic method for nucleic acid amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5779907A (en) 1996-12-06 1998-07-14 Systems Research Laboratories, Inc. Magnetic microplate separator
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5849497A (en) 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
EP1005569A2 (en) 1997-08-01 2000-06-07 MorphoSys AG Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US5916776A (en) 1997-08-27 1999-06-29 Sarnoff Corporation Amplification method for a polynucleotide
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE418340T1 (de) 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
EP1077263A1 (de) 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
EP1354056B1 (en) 2000-10-10 2014-11-26 Danisco US Inc. Enhanced secretion of a polypeptide by a microorganism
US7094571B2 (en) 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
ATE298794T1 (de) 2000-12-20 2005-07-15 Altana Pharma Ag Verfahren zur herstellung und reinigung von sekretierten proteinen und herstellung von protein-arrays
US7098302B2 (en) 2001-10-12 2006-08-29 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of ErbB2 and uses therefor
US7419783B2 (en) 2001-11-05 2008-09-02 Research Development Foundation Engineering of leader peptides for the secretion of recombinant proteins in bacteria
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
CA2480159A1 (en) 2002-03-23 2003-10-09 Research Development Foundation Secretion of proteins with multiple disulfide bonds in bacteria and uses thereof
US7611866B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Selection of bacterial inner-membrane anchor polypeptides
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7229792B2 (en) 2004-05-03 2007-06-12 Vinod Pandiripally Method of producing recombinant proteins
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US20150315284A1 (en) 2004-11-09 2015-11-05 Xencor, Inc. OPTIMIZED Fc VARIANTS
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
EP1851251A2 (en) 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2008030564A2 (en) * 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
US20100184959A1 (en) 2007-03-19 2010-07-22 Medimmune Limited Polypeptide Variants
US8629245B2 (en) 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
US8043621B2 (en) 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
EP2229410A4 (en) 2007-12-05 2012-07-04 Massachusetts Inst Technology AGLYCOSYLATED IMMUNOGLOBULIN MUTANES
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
JP5683581B2 (ja) 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
WO2011025826A1 (en) 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2826467C (en) 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
BR112013021526B1 (pt) 2011-02-25 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
JP5893346B2 (ja) 2011-11-07 2016-03-23 キヤノン株式会社 画像符号化装置、画像符号化方法及びプログラム、画像復号装置、画像復号方法及びプログラム
CA2877346C (en) 2012-06-25 2021-03-09 Research Development Foundation Method for engineering proteases and protein kinases
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains

Similar Documents

Publication Publication Date Title
JP2018505893A5 (enExample)
KR102609197B1 (ko) 인터류킨 15 단백질 복합체 및 그의 용도
US11535664B2 (en) Multi-valent hepatitis B virus antigen binding molecules and uses thereof
US20220169751A1 (en) Multimeric ox40 binding molecules and uses thereof
RU2689717C2 (ru) Гетеродимерный белок il-15 и его применения
JP2024113039A (ja) 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
ES2914177T3 (es) Anticuerpos anti-OX40 humanizados y usos de los mismos
ES2752248T3 (es) Heterodímero proteínico y uso del mismo
JP2016533753A5 (enExample)
JP2020530296A5 (enExample)
JP2017531427A5 (enExample)
CN110835374A (zh) 抗ccr8×ctla-4双特异性抗体及其应用
TW201841944A (zh) 4-1bbl變異體及包含其之融合蛋白
KR20200004292A (ko) 항 인터페론 감마 항체 및 그의 용도
KR20180088458A (ko) 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
CN109929037B (zh) 针对程序性死亡配体的结合物及其应用
CN116194471A (zh) 抗pd-1抗体和融合蛋白
CN110475857A (zh) 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
CN117222734A (zh) 靶向半乳凝素的免疫疗法
WO2014166029A1 (zh) 针对表皮生长因子受体的抗体
CA2566299C (en) Recombinant chemotactic antigen gene vaccine
JP7606173B2 (ja) Ｉ型インターフェロンの中和型Ｆｃ融合タンパク質及びその使用
WO2022099022A1 (en) Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
JP2022536850A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
WO2023060165A2 (en) Interleukin-10 muteins and fusion proteins thereof